Log In Sign up
The largest database of trusted experimental protocols
> Disorders > Sign or Symptom > Signs and Symptoms

Signs and Symptoms

Discover how PubCompare.ai simplifies your research by helping you locate the best protocols and products.
Our AI-powered comparisons analyze literature, pre-prints, and patents to enhance reproducibiolity and accuracy.
Easily find the optimal protocols for your research needs.

Most cited protocols related to «Signs and Symptoms»

1
Racial/Ethnic Differences in Fetal Growth

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2015
Birth Weight Cuboid Bone Ethnicity Females Fetal Growth Fetus Gestational Age Health Insurance Infant Males Pregnancy Tests Racial Groups Signs and Symptoms Student Ultrasonography Woman
2
Consensus on Reproductive Aging Staging
STRAW+10 involved a 2-day, in-person meeting hosted at the 2011 Annual Meeting of NAMS. On the first day, international experts gave oral presentations reviewing recent data bearing on the goals, as part of a public symposium, followed by comments and discussion from the audience. The first two sessions focused on data from prospective cohort studies of midlife women, clinical findings related to trajectories of change in menstrual, endocrine and ovarian markers of reproductive aging, and data relevant to how these trajectories vary by ethnicity, body size, and smoking status. A particular focus was on patterns of change in AMH, inhibin B, FSH, estradiol and AFC and their inter-relationships. A third session focused on emerging evidence related to staging reproductive aging in the context of cancer treatment, chronic illness including cancer and HIV-AIDS, and endocrine disorders including polycystic ovarian syndrome (PCOS) and primary ovarian insufficiency (POI, otherwise known as premature ovarian failure). At the end of day one, a panel reviewed and participants discussed modifications that had been proposed by symposium speakers. STRAW+10 explicitly considered feasibility of applying criteria in low resource countries.
Subsequently, 41 invited scientists convened to develop consensus and propose modifications to the STRAW model. These participants had clinical and/or research experience in female reproductive aging and included scientists from several key research groups in the United States, Canada, Australia, the Netherlands and South Africa, representatives from the NIH funded cohort studies of midlife women that have biological samples60 (link) including SWAN, the Michigan Bone Health and Metabolism Study (MBHMS), SMWHS, Biodemographic Models of Reproductive Aging (BIMORA), and the Penn Ovarian Aging Study (POAS) as well as the Australian MWMHP, as well as junior investigators who submitted qualifying posters.
Three breakout groups were formed based on scientific expertise and interest. Group 1 reviewed criteria for STRAW Stages −4 to −2. Group 2 reviewed criteria for STRAW Stages −1 to +2. Each of these two groups was subdivided into two subgroups and assigned a rapporteur. Each subgroup proposed modifications to the STRAW paradigm separately, considering criteria for the relevant stages in healthy women and the weight of evidence concerning the appropriateness of applying these criteria to smokers and women regardless of body size. Each subgroup of Group 1 and of Group 2 then reviewed the recommendations of their paired subgroup and discussed points of disagreement until consensus was reached. Group 3 discussed staging in the context of endocrine disorders and chronic illness and proposed modifications. This group then integrated with one of the Group 1 or Group 2 subgroups.
On the second day, the 41 scientists convened to review and discuss proposed modifications. First, Group 1 and Group 2 reviewed the other group’s recommendations proposed on the previous day. In this way, all groups reviewed all stages under consideration (Stages −4 to +2) Then, the group at-large met to discuss each proposal and final recommendations were adopted by consensus. Preliminary recommendations of the STRAW+10 Workshop were presented at the NAMS annual meeting on September 22 with comments and requests for clarification considered by the STRAW+10 program committee.
Harlow S.D., Gass M., Hall J.E., Lobo R., Maki P., Rebar R.W., Sherman S., Sluss P.M, & de Villiers T.J. (2012). EXECUTIVE SUMMARY of STRAW+10: Addressing the Unfinished Agenda of Staging Reproductive Aging. Climacteric : the journal of the International Menopause Society, 15(2), 105-114.
Publication 2012
Acquired Immunodeficiency Syndrome Biopharmaceuticals Body Size Bones Conferences Disease, Chronic Endocrine System Diseases Estradiol Ethnicity Females inhibin B Malignant Neoplasms Menstruation Metabolism Native American myopathy Ovarian Failure, Premature Ovary Polycystic Ovary Syndrome Reproduction Signs and Symptoms System, Endocrine Woman
3
Recruiting Consecutive MI Patients
The goal of TRIUMPH was to recruit a consecutive cohort of MI patients from each enrolling center. Because an important component of the study was to perform a detailed patient interview, patients needed to be prospectively identified as early as possible during their hospitalization. All patients with a positive troponin, as established by the norms of the recruiting center, were screened for possible inclusion. For sites with large volumes of MI patients, a systematic sampling strategy (e.g. screening every second or every third MI case based on the time of the first positive cardiac enzyme blood test and not convenience) was performed. Because the timing of consecutive positive laboratory tests is not influenced by patient characteristics or disease severity, no selection biases should have been introduced.
Once a patient was identified, a brief screening form was completed to establish eligibility. Only patients with a Type 1 acute MI34 (link) (i.e. spontaneous MI related to ischemia due to a primary coronary event) were eligible for enrollment. Patients had to fulfill the following criteria for eligibility: (1) ≥18 years, (2) elevated troponin level (cardiac enzyme elevation as a complication of elective coronary revascularization did not qualify), (3) clinical features of ischemia (e.g. prolonged ischemic signs/symptoms, electrocardiographic ST changes in ≥2 consecutive leads), and (4) initial presentation to the enrolling institution or transfer within the first 24 hours of original presentation. This latter criterion ensured that the primary clinical decision making was conducted at the enrolling site. Incarcerated patients were not eligible, and all patients signed an informed consent that was approved by each institution.
Arnold S.V., Chan P.S., Jones P.G., Decker C., Buchanan D.M., Krumholz H.M., Ho P.M, & Spertus J.A. (2011). Translational Research Investigating Underlying disparities in acute Myocardial infarction Patients’ Health status (TRIUMPH): Design and Rationale of a Prospective Multicenter Registry. Circulation. Cardiovascular Quality and Outcomes, 4(4), 467-476.
Publication 2011
BLOOD Cardiac Events Electrocardiography Eligibility Determination Enzymes Heart Hospitalization Ischemia Myocardial Revascularization Patients Signs and Symptoms Test, Clinical Enzyme Troponin
4
Validating Verbal Autopsy in Golestan Cohort Study
The methods of the Golestan Cohort Study (GCS) have been previously described in detail [20] (link). In brief, 50,045 adult middle-aged individuals were enrolled in eastern Golestan Province, Iran between January 2004 and June 2008. Participants are actively followed through annual telephone contact to ascertain their vital and health status. If a participant cannot be reached, family members, friends, or local health workers are contacted. Moreover, local health workers in rural areas, called “Behvarz”, are contacted monthly to inquire about any possible outcomes, including death. In the event of death, the follow-up team performs two main tasks in parallel. First, a trained general practitioner goes to the homes of the family members or primary care givers of the deceased and conducts a VA interview. Second, the team determines which physicians or hospitals were visited by the decedent and obtains all medical documents (charts, X-rays, pathology reports, etc) that could be used to identify the cause of death. These documents may be available in Golestan or in neighboring provinces.
The GCS follow-up team uses the adult VA questionnaire originally developed by World Health Organization (WHO) and the International Network of field sites with continuous Demographic Evaluation of Populations and Their Health in developing countries (INDEPTH) [37] , [38] , with some modifications to adapt to the local situation in Golestan. We tailored the standard VA questionnaire based on cultural background and education of study population. We made special attention to the most common disease and causes of death in the study area. We added some disease-oriented questions for specific diseases (cardiovascular, stroke, cancer (esophageal and gastric), diabetes, hypertension, tuberculosis and asthma) to collect more information by VA. Since we have already collected the data of life style and personal habits of the study participants at the enrollment phase of GCS, we excluded this part of VA questionnaire to save time. Local terms for some signs/symptoms such as “dysphagia” were applied when we translated the VA questionnaire to Farsi.
After the VA interview and medical document search are completed, the results are given to two internists to ascertain the cause of death. The two internists who review the VA and other documents are unaware of each other's diagnosis. When they disagree on the cause of death, a third senior internist reviews the VA, the available documents, and also the diagnoses of the first two internists and makes the final decision. All causes of death are coded according to the core three digit codes of the International Classification of Diseases, Tenth Revision (ICD-10) [39] . The cause of death obtained by this method was considered as the gold standard for the current validation study. Seventy cases (32%) had no medical documents, so in these cases the VA-based diagnoses confirmed by the above method were used as the gold standard.
Khademi H., Etemadi A., Kamangar F., Nouraie M., Shakeri R., Abaie B., Pourshams A., Bagheri M., Hooshyar A., Islami F., Abnet C.C., Pharoah P., Brennan P., Boffetta P., Dawsey S.M, & Malekzadeh R. (2010). Verbal Autopsy: Reliability and Validity Estimates for Causes of Death in the Golestan Cohort Study in Iran. PLoS ONE, 5(6), e11183.
Full text: Click here
Publication 2010
Adult Aged Asthma Attention Deglutition Disorders Diabetes Mellitus Diagnosis Family Member Fingers Friend Gold Health Personnel High Blood Pressures Malignant Neoplasms Myocardial Infarction Physicians Signs and Symptoms Stomach Tuberculosis Workers X-Rays, Diagnostic
5
Consensus on Sjögren's Syndrome Criteria
In February 2004, the panel of experts gathered for a face-to-face meeting moderated by a statistician (SCS) and an epidemiologist (CHS). The goal of this meeting was to obtain consensus (at least 80%) on the target population to whom the classification criteria would apply, and the initial list of variables or criteria items that would be collected as part of SICCA. The meeting began with presentation of a comprehensive literature review by one of the senior investigators (TED) of the 11 previous classification and diagnostic criteria for SS that had been published in the past 40 years, none of which had been endorsed by the ACR or EULAR.
There was consensus among the panel that the criteria should apply to the population of patients who may be referred to a specialist because of signs and/or symptoms possibly suggesting SS. Recruitment strategies and eligibility criteria are described below. The rationale for selecting this target population is that a given patient would not be evaluated for SS unless she/he had signs or symptoms suggesting this diagnosis. There was also consensus that if asked to select cases and controls for validation of new classification criteria, panel members would use objective tests (e.g., specific serum measures of autoimmunity, ocular staining reflecting lacrimal hypofunction, and LSG biopsy reflecting FLS) that would likely be part of the new classification criteria, leading to circularity. Therefore, it was agreed that no diagnostic labels would be used for enrollment, and that all participants would undergo the same set of standardized objective tests, and questionnaires capturing various signs and symptoms.
The panel agreed upon examinations and tests used to assess ocular and oral signs and symptoms, tear and salivary function, LSG biopsy results and various serum measures of autoimmunity. The list created was based both on published results and on the clinical experience of panel members. There was discussion among the rheumatologists regarding which extra-glandular manifestations possibly associated with SS should be captured, and a consensus was achieved regarding a list of signs/symptoms that would be measured through a targeted rheumatologic examination, review of systems, careful medical history and serologic laboratory measures. Similarly, the oral medicine specialists agreed on a list of tests measuring salivary function (both stimulated parotid and UWS flow rates), and salivary gland expression of autoimmunity through biopsy of LSG, examining them for the presence of FLS, and measuring FS accordingly as described in detail elsewhere (15 (link)). The ophthalmologists agreed on tests evaluating participants for the presence of keratoconjunctivitis sicca (KCS). There was consensus that, while rose Bengal had been widely used for grading conjunctival and corneal damage in patients with KCS, it is inherently toxic to epithelial cells and very painful for patients. Therefore, fluorescein was selected to grade the cornea and lissamine green the bulbar conjunctiva. Effectiveness for grading KCS is established for both (16 (link)). They agreed on a standardized quantitative grading system that would be easily reproducible and could be used in clinical practice in the future (17 (link)). Ocular staining score (OSS) is the sum of a 0–6 score for fluorescein staining of the cornea and a 0–3 score for lissamine green staining of both nasal and temporal bulbar conjunctivae, yielding a total score ranging from 0 to 12. Alternative established tests for dryness used in prior criteria, such as tear break-up time (TBUT) and unanesthetized Schirmer test, were also included.
The final list of criteria items that was agreed upon by the end of the first meeting included nearly all those previously reported in the relevant literature. It has been described previously (12 (link)) and is available at http://sicca.ucsf.edu.
Shiboski S., Shiboski C., Criswell L., Baer A., Challacombe S., Lanfranchi H., Schiødt M., Umehara H., Vivino F., Zhao Y., Dong Y., Greenspan D., Heidenreich A., Helin P., Kirkham B., Kitagawa K., Larkin G., Li M., Lietman T., Lindegaard J., McNamara N., Sack K., Shirlaw P., Sugai S., Vollenweider C., Whitcher J., Wu A., Zhang S., Zhang W., Greenspan J, & Daniels T. (2012). American College of Rheumatology Classification Criteria for Sjögren’s Syndrome: A Data-Driven, Expert Consensus Approach in the SICCA Cohort. Arthritis care & research, 64(4), 475-487.
Publication 2012
Autoimmunity Biopsy Conjunctiva Conjunctiva, Bulbar Cornea Cornea Injuries Diagnosis Eligibility Determination Epidemiologists Epithelial Cells Eye Face Fast Green FCF Fluorescein Keratoconjunctivitis Sicca Nose Ophthalmologists Pain Parotid Gland Patients Physical Examination Rheumatologist Rose Bengal Salivary Glands Serum Signs and Symptoms Specialists Target Population Tears

Most recents protocols related to «Signs and Symptoms»

1
Hospital Billing Diagnosis Codes
For billing purposes, each hospital stay contains a limited set of diagnosis codes. These codes usually include the most important diagnoses during the hospital stay; however, financial concerns and imperfect mapping of clinical findings to predetermined codes can impact this.
Sotoodeh M., Zhang W., Simpson R.L., Hertzberg V.S, & Ho J.C. (2023). A Comprehensive and Improved Definition for Hospital-Acquired Pressure Injury Classification Based on Electronic Health Records: Comparative Study. JMIR Medical Informatics, 11, e40672.
Full text: Click here
Publication 2023
Diagnosis Signs and Symptoms
2
Multivariate analysis of ALFF in MDD
Age, CDI scores, and years of education were compared between MDD patients and control individuals using two-sample t-tests, whereas gender distributions were compared with Chi-square tests. SPSS 22.0 was used for statistical analyses. Correlations between abnormal ALFF values and specific clinical findings were assessed via Pearson correlation analyses. p < 0.05 were considered significant.
A voxel-by-voxel covariance analysis of individual whole-brain ALFF maps was used to detect differences between the two study cohorts. Analyzed covariates included age, years of education, and framewise displacement. REST was used for the GRF correction of results at p < 0.01 (cluster significance: p < 0.01, voxel significance: p < 0.001).
Zhou Y., Song Y., Chen C., Yan S., Chen M, & Liu T. (2023). Abnormal amplitude of low-frequency fluctuation values as a neuroimaging biomarker for major depressive disorder with suicidal attempts in adolescents: A resting-state fMRI and support vector machine analysis. Frontiers in Psychology, 14, 1146944.
Full text: Click here
Publication 2023
Brain Mapping Gender Patients Signs and Symptoms
3
Baduanjin Exercise Trial for Chronic Heart Failure
This was a cross-sectional study as well as a part of the Baduanjin-Eight-Silken-Movement with Self-efficacy Building for Patients with Chronic Heart Failure (BESMILE-HF) trial (NCT03180320, ClinicalTrials.gov, registration date: 08/06/2017) [6 (link)]. Patients with CHF were prospectively recruited between February 2019 and July 2022 if they fulfilled the following inclusion criteria: (1) ≥ 18 years of age; (2) met the diagnostic criteria for CHF [7 (link)]; (3) clinically stable, defined as symptoms/signs that remained generally unchanged for ≥ 1 month; (4) New York Heart Association class II or III; (5) used beta-blockers; and (6) provided informed consent [8 (link)].
The exclusion criteria were as follows: (1) patients with contraindications for exercise testing, namely, early phase after acute coronary syndrome (up to 6 weeks), life-threatening cardiac arrhythmias, acute heart failure (during the initial period of hemodynamic instability), uncontrolled hypertension (systolic blood pressure > 200 mmHg and/or diastolic blood pressure > 110 mmHg), advanced atrioventricular block, acute myocarditis and pericarditis, moderate to severe aortic valve/mitral stenosis, severe aortic valve/mitral regurgitation, severe hypertrophic obstructive cardiomyopathy, acute systemic illness, or intracardiac thrombus; (2) patients with serious acute or chronic diseases affecting major organs or with mental disorders; (3) patients with a history of cardiac surgery, cardiac resynchronization therapy, intracardiac defibrillation, or implantation of a combined device within the previous 3 months; (4) patients with a history of cardiac arrest within 1 year; (5) patients with a history of peripartum cardiomyopathy, hyperthyroid heart disease, or primary pulmonary hypertension; and (6) patients unable to perform a recumbent bicycle stress test (Fig. 1) [6 (link)].

Flow chart of this study

Eligible participants underwent clinical evaluation (including history of cardiac risk factors and medications), height and weight measurements, blood testing, and electrocardiography. They then underwent a cardiopulmonary exercise test (CPET) and transthoracic echocardiography assessment at rest on the same day (Fig. 2A, B). The BESMILE-HF study[6 (link)] was approved by the Ethics Committee of the Guangdong Provincial Hospital of Chinese Medicine (Approval No. B2016-202-01). All of the participants provided written informed consent.

Illustration of speckle-tracking echocardiography examination (A) and cardiopulmonary exercise testing (B). Strain analysis of the left atrium in the locally enlarged apical four-chamber view and the LA strain curve throughout the cardiac cycle (C). The curves of VO2 and VCO2 with time and work rate, respectively (D). LA, left atrial; VO2, oxygen uptake; VCO2, carbon dioxide uptake; VO2max/pre, ratio of maximum to predicted oxygen uptake, WR, work rate

Sun P., Cen H., Chen S., Chen X., Jiang W., Zhu H., Liu Y., Liu H, & Lu W. (2023). Left atrial dysfunction can independently predict exercise capacity in patients with chronic heart failure who use beta-blockers. BMC Cardiovascular Disorders, 23, 128.
Full text: Click here
Publication 2023
Acute Coronary Syndrome Adrenergic beta-Antagonists Aortic Valve Insufficiency Aortic Valve Stenosis Atrioventricular Block Atrium, Left Carbon dioxide Cardiac Arrest Cardiac Arrhythmia Cardiac Resynchronization Therapy Cardiomyopathies Chinese Diagnosis Disease, Chronic Echocardiography Electric Countershock Electrocardiography Ethics Committees, Clinical Exercise Tests Heart Heart Diseases Heart Failure Hemodynamics High Blood Pressures Hyperthyroidism Hypertrophic Obstructive Cardiomyopathy Idiopathic Pulmonary Arterial Hypertension Medical Devices Mental Disorders Movement Myocarditis Ovum Implantation Oxygen Patients Pericarditis Pharmaceutical Preparations Pressure, Diastolic Signs and Symptoms Silk Strains Surgical Procedure, Cardiac Systolic Pressure Thrombus
4
Comparing ENKL and DLBCL clinical features
The primary outcomes were the characteristic clinical manifestations and
laboratory findings of ENKL compared with those of DLBCL. The secondary outcomes
were OS in ENKL and DLBCL involving the nasal cavity and paranasal sinuses.
Tanaka H., Mori E., Akutsu T., Saito S., Tei M, & Otori N. (2023). Characteristics of Extranodal NK/T-Cell Lymphoma, Nasal Type, Compared with Nasal Diffuse Large B-cell Lymphoma. Clinical Medicine Insights. Oncology, 17, 11795549231156692.
Publication 2023
Nasal Cavity Signs and Symptoms Sinuses, Nasal
5
Factors Affecting Outcomes in Pleural Infection
The present study is a retrospective cohort study. Patients were divided into two groups: non-survivors and survivors at 3 months. The following variables from medical records were investigated: (1) patient factors (sex, presence of dysphagia, compromised-host, smoking history); (2) clinical findings factors, such as CRP, WBC, blood urea nitrogen (BUN), age, purulence of pleural fluid, infection source (community-acquired/hospital-acquired), serum albumin, OHAT score, and etiology (monomicrobial/polymicrobial/no growth); and (3) treatment methods. Dysphagia was defined as coughing when taking a meal or decreasing swallowing ability on evaluation by physicians and speech-language-hearing therapists [7 (link)]. Data on treatment and outcomes were also evaluated for each patient during hospitalization. A compromised-host was defined as a patient with any of the following diseases: rheumatoid arthritis, chronic kidney disease, malignancy, diabetes, cardiovascular diseases, neurological diseases, and steroid use. We used two clinical risk scores: RAPID (total score; min:0 point, max:7 points) and OHAT (total score; min:0 point, max:16 points). The RAPID score was based on five common parameters (Table 1) [6 (link)]. Based on the results of the dental examinations, the presence of teeth with poor prognosis was retrospectively investigated using panoramic dental radiography. They were defined as teeth with abnormal radiographic findings (e.g., apical radiolucency larger than 3 mm in diameter, alveolar bone loss around more than half of the root, untreated root remnants, or vertically fractured roots) [19 ,20 ]. Medical records were used whether those teeth were extracted. Pleural fluid was collected by pleural puncture at the time of admission, and microbiological examinations were performed. Anaerobic containers were used to collect pleural fluid to detect anaerobic bacteria, and Gram staining and pleural fluid cultures were performed. Blood agar (Kohjin Bio Co., Ltd., Saitama, Japan) and chocolate agar media (Kohjin Bio Co., Ltd.) were used to detect general bacteria. Anaero Columbia agar medium with hemin and vitamin K1 (Nippon Becton Dickinson Co., Ltd., Tokyo, Japan) was used to detect anaerobic bacteria; any anaerobic bacteria were then cultivated at 35°C and 9% CO2. The causative pathogens were then identified in the pleural fluid culture.
Iwata E., Nishiuma T., Hori S., Sugiura K., Taki M., Tokunaga S., Kusumoto J., Hasegawa T., Tachibana A, & Akashi M. (2023). Relationship between oral health and prognosis in patients with empyema: Single center retrospective study with propensity score matching analysis. PLOS ONE, 18(3), e0282191.
Full text: Click here
Publication 2023
Agar Alveolar Bone Loss Bacteria Bacteria, Anaerobic BLOOD Cacao Cardiovascular Diseases Chronic Kidney Diseases Deglutition Disorders Dental Health Services Diabetes Mellitus Hemin Hospitalization Infection Malignant Neoplasms Nervous System Disorder Panoramic Radiography pathogenesis Patients Physical Examination Physicians Plant Roots Pleura Prognosis Punctures Radiography, Dental Rheumatoid Arthritis Serum Albumin Signs and Symptoms Speech Steroids Survivors Tooth Tooth Root Urea Nitrogen, Blood Vitamin K1 X-Rays, Diagnostic

Top products related to «Signs and Symptoms»

1
Sas version 9 by SAS Institute
Sourced in United States, Austria, Japan, Cameroon, Germany, United Kingdom, Canada, Belgium, Israel, Denmark, Australia, New Caledonia, France, Argentina, Sweden, Ireland, India
SAS version 9.4 is a statistical software package. It provides tools for data management, analysis, and reporting. The software is designed to help users extract insights from data and make informed decisions.
2
Spss version 25 by IBM
Sourced in United States, United Kingdom, Japan, Austria, Germany, Denmark, Czechia, Belgium, Sweden, New Zealand, Spain
SPSS version 25 is a statistical software package developed by IBM. It is designed to analyze and manage data, providing users with a wide range of statistical analysis tools and techniques. The software is widely used in various fields, including academia, research, and business, for data processing, analysis, and reporting purposes.
3
Spss statistic by IBM
Sourced in United States, Japan, United Kingdom, Germany, Belgium, Austria, Italy, Poland, India, Canada, Switzerland, Spain, China, Sweden, Brazil, Australia, Hong Kong
SPSS Statistics is a software package used for interactive or batched statistical analysis. It provides data access and management, analytical reporting, graphics, and modeling capabilities.
4
Spss version 20 by IBM
Sourced in United States, Japan, United Kingdom, Germany, Belgium, Austria, Spain, France, Denmark, Switzerland, Ireland
SPSS version 20 is a statistical software package developed by IBM. It provides a range of data analysis and management tools. The core function of SPSS version 20 is to assist users in conducting statistical analysis on data.
5
Spss v20 by IBM
Sourced in United States, Germany, United Kingdom, Belgium, Japan, China, Austria, Denmark
SPSS v20 is a statistical software package developed by IBM. It provides data management, analysis, and visualization capabilities. The core function of SPSS v20 is to enable users to perform a variety of statistical analyses on data, including regression, correlation, and hypothesis testing.
6
Sas 9 by SAS Institute
Sourced in United States, Austria, Japan, Belgium, United Kingdom, Cameroon, China, Denmark, Canada, Israel, New Caledonia, Germany, Poland, India, France, Ireland, Australia
SAS 9.4 is an integrated software suite for advanced analytics, data management, and business intelligence. It provides a comprehensive platform for data analysis, modeling, and reporting. SAS 9.4 offers a wide range of capabilities, including data manipulation, statistical analysis, predictive modeling, and visual data exploration.
7
Spss version 21 by IBM
Sourced in United States, Japan, United Kingdom, Germany, Austria, Belgium, Denmark, China, Israel, Australia
SPSS version 21 is a statistical software package developed by IBM. It is designed for data analysis and statistical modeling. The software provides tools for data management, data analysis, and the generation of reports and visualizations.
8
R version 3 by R Project for Statistical Computing
Sourced in United States, Austria, Japan, Belgium, New Zealand, United Kingdom, Germany, Denmark, Australia, France
R version 3.6.1 is a statistical computing and graphics software package. It is an open-source implementation of the S programming language and environment. R version 3.6.1 provides a wide range of statistical and graphical techniques, including linear and nonlinear modeling, classical statistical tests, time-series analysis, classification, clustering, and more.
9
Prism 7 by GraphPad
Sourced in United States, Japan, United Kingdom, Austria, Canada, Germany, Poland, Belgium, Lao People's Democratic Republic, China, Switzerland, Sweden, Finland, Spain, France
GraphPad Prism 7 is a data analysis and graphing software. It provides tools for data organization, curve fitting, statistical analysis, and visualization. Prism 7 supports a variety of data types and file formats, enabling users to create high-quality scientific graphs and publications.

More about "Signs and Symptoms"

Manifestations, Clinical Features, Symptomatology, Presentations, Indications, Phenotypes, Expressions, Syndromes, Complaints, Markers, Signals, Indicators, Diagnostic Criteria, Diagnostic Signs, Diagnostic Symptoms, Diagnostic Manifestations, Diagnostic Presentations, Diagnostic Expressions, Diagnostic Phenotypes, Diagnostic Syndromes, Diagnostic Complaints, Diagnostic Markers, Diagnostic Signals, Diagnostic Indicators, Analytical Techniques, Statistical Analysis, Data Analysis, Hypothesis Testing, Probability, Regression, Correlation, ANOVA, t-Test, Chi-Square, GraphPad, SAS, SPSS, R, Statistical Software